方盛製藥(603998.SH):以0元受讓星辰創投400萬份財產份額(未實繳)
格隆匯12月10日丨方盛製藥(603998.SH)公佈,公司於2021年12月10日與湖南康慈簽署了《財產份額轉讓協議》,公司以0元受讓湖南康慈企業管理諮詢合夥企業(有限合夥)(“湖南康慈”)持有的長沙星辰創新創業投資合夥企業(有限合夥)(“星辰創投”)400萬份財產份額(未實繳);上述財產份額完成受讓後,公司將直接持有星辰創投3775萬份財產份額(其中實繳出資3375萬元,未實繳出資400萬元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.